R. 1. Tracey, D. Klareskog, L. Sasso, E. Salfeld, J. Tak et al., Tumor necrosis factor antagonist mechanisms of action: A comprehensive review, Pharmacology & Therapeutics, vol.117, issue.2, pp.244-79, 2008.
DOI : 10.1016/j.pharmthera.2007.10.001

T. Bongartz, A. Sutton, M. Sweeting, I. Buchan, E. Matteson et al., Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19
DOI : 10.1001/jama.295.19.2275

M. Flendrie, M. Creemers, P. Welsing, A. Broeder, and P. Van-riel, Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.62, issue.90002
DOI : 10.1136/ard.62.suppl_2.ii30

J. Zeichner and M. Lebwohl, Potential Complications Associated with the Use of Biologic Agents for Psoriasis, Dermatologic Clinics, vol.25, issue.2, pp.207-220, 2007.
DOI : 10.1016/j.det.2007.01.010

J. Ko, A. Gottlieb, and J. Kerbleski, Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases, Journal of Dermatological Treatment, vol.174, issue.15, pp.100-108, 2009.
DOI : 10.1016/S0140-6736(02)08512-4

G. Mocci, M. Marzo, A. Papa, A. Armuzzi, and L. Guidi, Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease, Journal of Crohn's and Colitis, vol.7, issue.10, pp.769-79, 2013.
DOI : 10.1016/j.crohns.2013.01.009

A. Collamer, K. Guerrero, J. Henning, and D. Battafarano, Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action, Arthritis & Rheumatism, vol.44, issue.7, pp.996-1001, 2008.
DOI : 10.1002/art.23835

G. Fiorino, M. Allez, A. Malesci, and S. Danese, Review article: anti TNF-?? induced psoriasis in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.27, issue.9, pp.921-928, 2009.
DOI : 10.1111/j.1365-2036.2009.03955.x

G. Cullen, D. Kroshinsky, A. Cheifetz, and J. Korzenik, Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature, Aliment Pharmacol Ther. déc, vol.34, pp.11-121318, 2011.

D. Cicchetti, J. Landis, and G. Koch, Assessing inter-rater reliability for rating scales: resolving some basic issues The measurement of observer agreement for categorical data, Br J Psychiatry J Ment Sci. nov, vol.129, issue.11, 1976.

N. Van-den-bossche, D. Vos, M. Naeyaert, and J. , Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy, 159?74. 12. Devos SA, pp.388-90, 1977.

J. Seneschal, S. Lepreux, B. Milpied, T. Schaeverbeke, and A. Taïeb, Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not?, Arch Dermatol. déc, vol.143, issue.12, pp.1593-1598, 2007.

J. Seneschal, S. Lepreux, M. Bouyssou-gauthier, I. Héliot-hosten, A. Economu et al., Psoriasiform Drug Eruptions Under Anti-TNF Treatment of Arthritis are Not True Psoriasis, 77?80. 15. Tillack C, Ehmann LM, 2007.
DOI : 10.2340/00015555-0193

. Anti-tnf-antibody, T. Walters, M. Tabbers, K. Frost, M. Zachos et al., induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-?-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment Infliximabinduced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms, 567?77. 16. Sherlock ME, pp.512-520, 2013.

J. Seneschal, B. Milpied, B. Vergier, S. Lepreux, T. Schaeverbeke et al., Cytokine imbalance with increased production of interferon-?? in psoriasiform eruptions associated with antitumour necrosis factor-?? treatments, British Journal of Dermatology, vol.202, issue.5, pp.1081-1089, 2009.
DOI : 10.1111/j.1365-2133.2009.09329.x

E. Manni, P. Barachini, P. Sfikakis, G. Kollias, A. Palucka et al., Psoriasis induced by infliximab in a patient suffering from Crohn's disease Tumor necrosis factor biology in experimental and clinical arthritis Cross-regulation of TNF and IFN-alpha in autoimmune diseases Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions, 3372?7. 21. de Gannes GC, pp.223-254, 2003.

D. Aeberli, M. Seitz, P. Jüni, P. Villiger, L. Bella et al., Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors Efalizumab-induced guttate psoriasis. Successful management and re-treatment Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects, 182?4. 24. Firmin D, pp.203-209, 2005.

B. 1. Deleo, A. Shiku, H. Takahashi, T. John, M. Old et al., Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma, Journal of Experimental Medicine, vol.146, issue.3, pp.720-754, 1977.
DOI : 10.1084/jem.146.3.720

E. Carswell, L. Old, R. Kassel, S. Green, N. Fiore et al., An endotoxin-induced serum factor that causes necrosis of tumors., Proceedings of the National Academy of Sciences, vol.72, issue.9, pp.3666-70, 1975.
DOI : 10.1073/pnas.72.9.3666

. Disponible-sur, Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française -Anti-TNF_V_Goeb.pdf [Internet]. [cité 23 sept 2015] Disponible sur: http://sfr.larhumatologie.fr/rc/rhumatologie Disponible sur: https://www.getaid.org/images/outils/adalimumab_maj_2011_dp, Disponible sur, 2013.

D. Laharie, A. Steinborn, F. Schnitzler, C. Tillack, S. Breiteneicher et al., with refractory IBD--pro: anti-TNF or immunosuppressive treatment 1:116?21. 13. Sousa P, Allez M. Complications of biologics in inflammatory bowel disease Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti- TNF alpha antibodies, 296?302. 14. Beigel F, pp.735-779, 2014.
DOI : 10.1159/000367861

G. Mocci, M. Marzo, A. Papa, A. Armuzzi, L. Guidi et al., Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease Psoriasiform eruption induced by infliximab Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction, 769?79. 16. Verea MM, pp.223-254, 2004.

J. Seneschal, S. Lepreux, M. Bouyssou-gauthier, I. Héliot-hosten, A. Economu et al., Psoriasiform Drug Eruptions Under Anti-TNF Treatment of Arthritis are Not True Psoriasis, Acta Dermato-Venereologica, vol.87, issue.1, pp.77-80, 2007.
DOI : 10.2340/00015555-0193

J. Seneschal, B. Milpied, B. Vergier, S. Lepreux, T. Schaeverbeke et al., Cytokine imbalance with increased production of interferon-?? in psoriasiform eruptions associated with antitumour necrosis factor-?? treatments, British Journal of Dermatology, vol.202, issue.5, pp.1081-1089, 2009.
DOI : 10.1111/j.1365-2133.2009.09329.x

P. Richette, M. Viguier, H. Bachelez, and T. Bardin, Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?):438?9. 22. English PL, Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab, J Rheumatol. févr J Cutan Med Surg. févr, vol.3413, issue.21, pp.40-42, 2007.

E. Manni, P. Barachini, A. Palucka, J. Blanck, L. Bennett et al., Psoriasis induced by infliximab in a patient suffering from Crohn's disease Cross-regulation of TNF and IFN-alpha in autoimmune diseases, Int J Immunopathol Pharmacol. sept Proc Natl Acad Sci U S A. 1 mars, vol.22102, issue.249, pp.3372-3379, 2005.

D. Aeberli, M. Seitz, P. Jüni, P. Villiger, J. Qin et al., Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors Role of NFkappaB in the apoptotic-resistant phenotype of keratinocytes, Rheumatol Oxf Engl. févr J Biol Chem. 31 déc, vol.44274, issue.253, pp.172-177, 1999.

J. Ko, A. Gottlieb, J. Kerbleski, L. Bella, S. Gaudiello et al., Induction and exacerbation of psoriasis with TNFblockade therapy: a review and analysis of 127 cases100?8. 29. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD Efalizumab-induced guttate psoriasis. Successful management and re-treatment Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects, 203?6. 32. Tillack C, Ehmann LM, 2008.

. Anti, M. Sherlock, T. Walters, M. Tabbers, K. Frost et al., Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment Infliximabinduced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease, 512?8. 34. Fiorino G, pp.921-928, 2009.

D. Gershov, S. Kim, N. Brot, and K. Elkon, Crohn's disease: a prospective cohort study C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity, 32?9. 361353?64. 37. Casiano CA, Tan EM. Recent developments in the understanding of antinuclear autoantibodies308?13. 38. Hanauer SB, 1996.

T. Sakai, M. Kawaguchi, S. Ishizawa, T. Kaji, K. Kitagawa et al., Histological features of palatine tonsils in pustulosis palmaris et plantaris: A morphometric study, Pathology International, vol.401, issue.Suppl., pp.186-93, 1994.
DOI : 10.1111/j.1440-1827.1994.tb02591.x

Y. Teranishi, H. Mizutani, M. Murata, M. Shimizu, K. Matsushima et al., Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: relation to focal infection and response to treatments Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action, 8?15. 41. Collamer AN, pp.996-1001, 1995.

O. Sokumbi, D. Wetter, A. Makol, K. Warrington, R. Null et al., Vasculitis associated with tumor necrosis factor-? inhibitors Autoimmune diseases induced by biological agents: a double-edged sword?, ):739?45. 43. Ramos-Casals M188?93. 44. Wiik A. Drug-induced vasculitis, pp.35-44, 2008.

M. Costa, N. Said, and B. Zimmermann, Drug-Induced Lupus due to Anti-Tumor Necrosis Factor ?? Agents, Seminars in Arthritis and Rheumatism, vol.37, issue.6, pp.381-388, 2008.
DOI : 10.1016/j.semarthrit.2007.08.003

D. Bandt, M. Sibilia, J. , L. Loët, X. Prouzeau et al., Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey, Arthritis Research & Therapy, vol.7, issue.3, pp.545-51, 2005.
DOI : 10.1186/ar1715

G. Ferraccioli, F. Mecchia, D. Poi, E. Fabris, and M. , Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections, Annals of the Rheumatic Diseases, vol.61, issue.4, pp.358-61, 2002.
DOI : 10.1136/ard.61.4.358

D. Wendling, C. Biver-dalle, C. Vidon, C. Prati, F. Aubin et al., Lichen planus under anti TNF therapy for ankylosing spondylitis Letter: Lichenoid eruption induced by etanercept, Jt Bone Spine Rev Rhum. mars Dermatol Online J. juill, vol.8018, issue.27, pp.227-235, 2012.

N. Van-den-bossche, D. Vos, M. Naeyaert, J. Richette, P. Bachelez et al., Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapyParadoxical cutaneous manifestations during anti-TNF-alpha therapy], 883?6. 51. Devos SA388?90. 52. Viguier M, pp.64-71, 2003.

M. Guerin, B. Haettich, C. Bara, L. Artru, B. Prophette et al., Lupus attributable to anti-TNF therapy and revealed by interstitial granulomatous dermatitis, Rheumatology International, vol.126, issue.1
DOI : 10.1007/s00296-011-2016-6

M. Ferran, J. Calvet, M. Almirall, R. Pujol, and J. Maymó, Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-?? blocker agents, Journal of the European Academy of Dermatology and Venereology, vol.53, issue.4, pp.479-84, 2011.
DOI : 10.1111/j.1468-3083.2010.03770.x

L. Bidre, E. Chaby, G. Martin, L. Perrussel, M. Sassolas et al., Pelade au cours d???un traitement par anti-TNF alpha??: neuf cas, Annales de Dermatologie et de V??n??r??ologie, vol.138, issue.4, pp.285-93, 2011.
DOI : 10.1016/j.annder.2011.01.047

R. Denadai, F. Teixeira, F. Steinwurz, R. Romiti, R. Saad-hossne et al., Induction or exacerbation of psoriatic lesions during anti-TNF-? therapy for inflammatory bowel disease: a systematic literature review based on 222 cases Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature, 517?24. 58, pp.11-121318, 2011.

M. Harrison, W. Dixon, K. Watson, Y. King, R. Groves et al., Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor ?? therapy: results from the British Society for Rheumatology Biologics Register, Annals of the Rheumatic Diseases, vol.68, issue.2, pp.209-224, 2009.
DOI : 10.1136/ard.2007.087288